WAYPOINT：对于鼻息肉患者，我们已经做到了吗？

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-06-13 DOI:10.1016/j.medj.2025.100701

Jack L Birkenbeuel, Vinay K Rathi

{"title":"WAYPOINT：对于鼻息肉患者，我们已经做到了吗？","authors":"Jack L Birkenbeuel, Vinay K Rathi","doi":"10.1016/j.medj.2025.100701","DOIUrl":null,"url":null,"abstract":"The WAYPOINT trial demonstrated that tezepelumab treatment for chronic sinusitis with nasal polyposis was associated with statistically significant and clinically meaningful reductions vs. placebo in both objective (nasal polyp score and rates of rescue steroids or surgery) and subjective (nasal congestion, loss of smell, and sinonasal outcomes test scores) measures of disease burden at 52 weeks.1.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 6","pages":"100701"},"PeriodicalIF":12.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"WAYPOINT: Are we there yet for patients with nasal polyposis?\",\"authors\":\"Jack L Birkenbeuel, Vinay K Rathi\",\"doi\":\"10.1016/j.medj.2025.100701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The WAYPOINT trial demonstrated that tezepelumab treatment for chronic sinusitis with nasal polyposis was associated with statistically significant and clinically meaningful reductions vs. placebo in both objective (nasal polyp score and rates of rescue steroids or surgery) and subjective (nasal congestion, loss of smell, and sinonasal outcomes test scores) measures of disease burden at 52 weeks.1.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 6\",\"pages\":\"100701\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2025.100701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2025.100701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

WAYPOINT试验表明，与安慰剂相比，tezepelumab治疗慢性鼻窦炎伴鼻息肉患者在52周时的客观（鼻息肉评分和救援类固醇或手术的比率）和主观（鼻塞、嗅觉丧失和鼻窦结局测试评分）疾病负担指标均有统计学意义和临床意义的降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

WAYPOINT: Are we there yet for patients with nasal polyposis?

The WAYPOINT trial demonstrated that tezepelumab treatment for chronic sinusitis with nasal polyposis was associated with statistically significant and clinically meaningful reductions vs. placebo in both objective (nasal polyp score and rates of rescue steroids or surgery) and subjective (nasal congestion, loss of smell, and sinonasal outcomes test scores) measures of disease burden at 52 weeks.¹.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.